"10.1371_journal.pone.0063818","plos one","2013-05-22T00:00:00Z","David Gardiner; Jay Lalezari; Eric Lawitz; Michael DiMicco; Rheem Ghalib; K Rajender Reddy; Kyong-Mi Chang; Mark Sulkowski; Steven Oâ€™ Marro; Jeffrey Anderson; Bing He; Vikram Kansra; Fiona McPhee; Megan Wind-Rotolo; Dennis Grasela; Mark Selby; Alan J Korman; Israel Lowy","Bristol-Myers Squibb, Pennington, New Jersey, United States of America; Quest Clinical Research, San Francisco, California, United States of America; Alamo Medical Research, San Antonio, Texas, United States of America; Advanced Clinical Research Institute, Anaheim, California, United States of America; The Liver Institute at Methodist Hospital, Dallas, Texas, United States of America; University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America; Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Springfield Clinic Infectious Diseases, Springfield, Illinois, United States of America; Bristol-Myers Squibb, Princeton, New Jersey, United States of America; Bristol-Myers Squibb, Wallingford, Connecticut, United States of America; Bristol-Myers Squibb, Milpitas, California, United States of America; Regeneron Pharmaceuticals, Tarrytown, New York, United States of America","Conceived and designed the experiments: D. Gardiner IL JA BH VK FM MWR D. Grasela M. Selby AJK. Performed the experiments: EL RG M. Sulkowski JL KRR KMC MD SO VK FM MWR. Analyzed the data: D. Gardiner IL JA BH VK FM MWR M. Selby AJK. Wrote the paper: DGr. Critically reviewed and edited the manuscript for content: D. Gardiner EL MD RG KRR KMC M. Sulkowski SO JA BE VK FM MWR D. Grasela M. Selby AJK IL.","This study was funded by Bristol-Myers Squibb. D. Grasela, JA, BH, D. Gardiner, VK, MWR, FM, MS and AK are/were employees of, and may hold stock in, Bristol-Myers Squibb (BMS). JL is employed by Quest Clinical Research, EL by Alamo Medical Research and IL by Medarex at the time of the study. Anti-PD-1 (BMS-936558) is a patented monoclonal antibody owned by BMS and currently in Phase 3 development as treatment for patients with chronic malignancy. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","05","David Gardiner","DG",18,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
